The Upadacitinib - New Janus Kinase Inhibitor - Literature Review
DOI:
https://doi.org/10.12775/QS.2024.21.54037Keywords
upadacitinib, atopic dermatitis, Janus kinase inhibitor, pruritusAbstract
Atopic dermatitis (AD) is a chronic, recurrent dermatosis that affects an increasing percentage of the population. It usually affects children and resolves spontaneously, however, symptoms can persist into adulthood and even appear de novo later in life. The skin lesions that appear in this disease significantly reduce patients quality of life. Visual skin symptoms are exacerbated during stress, and pruritus leads to sleep problems. The effect of an inadequately controlled disease can even be a reduction in social activities and a reluctance to leave the house. The basis of treatment is skin care using emollients and avoiding triggers and aggravating factors. In the next stage, the doctor may prescribe topical or systemic treatment for the patient, depending on the severity of the disease. Such measures may not be enough, so more and more new drugs are being registered for the treatment of atopic dermatitis. One of them is upadacitinib, which appears to be extremely effective compared to other medications used to treat moderate to severe ad. It is a selective JAK inhibitor that reduces the inflammatory response by inhibiting migration, proliferation and cytokine secretion by granulocytes. It brings rapid and sustained effects in reducing skin lesions and reducing one of the most bothersome symptoms, pruritus.It may serve as a good alternative to the existing methods for treating moderate to severe atopic dermatitis The purpose of our study is to describe this new drug, its mechanism of action and discuss its possible benefits versus side effects.
References
Asher, M. I., Montefort, S., Björkstén, B., Lai, C. K., Strachan, D. P., Weiland, S. K., Williams, H., & ISAAC Phase Three Study Group. (2006). Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. The Lancet, 368(9537), 733–743. https://doi.org/10.1016/S0140-6736(06)69283-0
Arrais, M., Lulua, O., Quifica, F., Rosado-Pinto, J., Gama, J. M. R., & Taborda-Barata, L. (2019). Prevalence of asthma, allergic rhinitis and eczema in 6-7-year-old schoolchildren from Luanda, Angola. Allergologia et Immunopathologia, 47(6), 523–534. https://doi.org/10.1016/j.aller.2018.12.002
Mallol, J., Crane, J., von Mutius, E., Odhiambo, J., Keil, U., Stewart, A., & ISAAC Phase Three Study Group. (2013). The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesis. Allergologia et Immunopathologia, 41(1), 73–85. https://doi.org/10.1016/j.aller.2012.03.001
Sacotte, R., & Silverberg, J. I. (2018). Epidemiology of adult atopic dermatitis. Clinical Dermatology, 36(5), 595–605. https://doi.org/10.1016/j.clindermatol.2018.05.007
Avena-Woods, C. (2017). Overview of atopic dermatitis. American Journal of Managed Care, 23(8 Suppl), S115–S123.
Chrostowska-Plak, D., Reich, A., & Szepietowski, J. C. (2013). Relationship between itch and psychological status of patients with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 27(2), e239–e242. https://doi.org/10.1111/j.1468-3083.2012.04578.x
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L., Grayson, M. H., Simpson, E. L., Ong, P. Y., & Fuxench, Z. C. C. (2018). Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Annals of Allergy, Asthma & Immunology, 121(3), 340–347. https://doi.org/10.1016/j.anai.2018.07.006
Xu, X., van Galen, L. S., Koh, M. J. A., Bajpai, R., Thng, S., Yew, Y. W., Ho, V. P. Y., Alagappan, U., Järbrink, K. S. A., & Car, J. (2019). Factors influencing quality of life in children with atopic dermatitis and their caregivers: A cross-sectional study. Scientific Reports, 9(1), 15990. https://doi.org/10.1038/s41598-019-51129-5
Drucker, A. M., Wang, A. R., Li, W. Q., Sevetson, E., Block, J. K., & Qureshi, A. A. (2017). The burden of atopic dermatitis: Summary of a report for the National Eczema Association. Journal of Investigative Dermatology, 137(1), 26–30. https://doi.org/10.1016/j.jid.2016.07.012
Parmentier, J. M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., & Friedman, M. (2018). In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatology, 2, 23.
Yamaoka, K., Saharinen, P., Pesu, M., Holt, V. E., Silvennoinen, O., & O’Shea, J. J. (2004). The Janus kinases (Jaks). Genome Biology, 5(12), 253. https://doi.org/10.1186/gb-2004-5-12-253
Cornez, I., Yajnanarayana, S. P., Wolf, A. M., & Wolf, D. (2017). JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs. Molecular and Cellular Endocrinology, 451, 88–96. https://doi.org/10.1016/j.mce.2017.01.035
Cotter, D. G., Schairer, D., & Eichenfield, L. (2018). Emerging therapies for atopic dermatitis: JAK inhibitors. Journal of the American Academy of Dermatology, 78(3 Suppl 1), S53–S62. https://doi.org/10.1016/j.jaad.2017.12.019
Fragoulis, G. E., McInnes, I. B., & Siebert, S. (2019). JAK inhibitors: New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford), 58(i43-i54).
Mease, P. J., Lertratanakul, A., Anderson, J. K., Papp, K., Van den Bosch, F., & Tsuji, S. (2021). Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Annals of the Rheumatic Diseases, 80(3), 312–320.
Blauvelt, A., Teixeira, H. D., Simpson, E. L., Costanzo, A., De Bruin-Weller, M., Barbarot, S., Prajapati, V. H., Lio, P., Hu, X., Wu, T., Liu, J., Ladizinski, B., Chu, A. D., & Eyerich, C. (2021). Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatology, 157(9), 1047–1055. https://doi.org/10.1001/jamadermatol.2021.3023
Katoh, N., Ikeda, M., Ohya, Y., Murota, H., Hu, X., Liu, J., Niiyama, H., Sasaki, T., Raymundo, E. M., & Saeki, H. (2024). Safety and efficacy of upadacitinib for atopic dermatitis in Japan: Analysis of the 3-year Phase 3 Rising Up study. Dermatology Therapy (Heidelberg), 14(1), 213–232. https://doi.org/10.1007/s13555-023-01071-2
Mendes-Bastos, P., Ladizinski, B., Guttman-Yassky, E., Jiang, P., Liu, J., Prajapati, V. H., Simpson, E. L., Vigna, N., Teixeira, H. D., & Barbarot, S. (2022). Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. Journal of the American Academy of Dermatology, 87(4), 784–791. https://doi.org/10.1016/j.jaad.2022.06.012
Simpson, E. L., Papp, K. A., Blauvelt, A., Chu, C. Y., Hong, H. C., Katoh, N., et al. (2022). Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatology, 158(4), 404–413.
Russell, M. D., Stovin, C., Alveyn, E., Adeyemi, O., Chan, C. K. D., Patel, V., Adas, M. A., Atzeni, F., Ng, K. K. H., Rutherford, A. I., Norton, S., Cope, A. P., & Galloway, J. B. (2023). JAK inhibitors and the risk of malignancy: A meta-analysis across disease indications. Annals of the Rheumatic Diseases, 82(8), 1059–1067. https://doi.org/10.1136/ard-2023-224049
Hagino, T., Yoshida, M., Hamada, R., Saeki, H., Fujimoto, E., & Kanda, N. (2024). Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis. Journal of Dermatological Treatment, 35(1), 2310643. https://doi.org/10.1080/09546634.2024.2310643
Martínez-Fernández, S., Suh-Oh, H. J., Batalla, A., Couselo-Rodríguez, C., Espasandín-Arias, M., & Flórez, Á. (2023). Retreatment with upadacitinib in atopic dermatitis: Experience in clinical practice. Journal of Dermatological Treatment, 34(1), 2242543. https://doi.org/10.1080/09546634.2023.2242543
Hagino, T., Hamada, R., Yoshida, M., Fujimoto, E., Saeki, H., & Kanda, N. (2023). Effectiveness and safety of upadacitinib in combination with topical corticosteroids in adolescent patients with moderate-to-severe atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology, 16, 3201–3212. https://doi.org/10.2147/CCID.S439053
Lansang, R. P., Zhao, I. X., & Lansang, P. (2023). Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report. SAGE Open Medical Case Reports, 11, 2050313X231180766. https://doi.org/10.1177/2050313X231180766
Nakashima, C., Yanagihara, S., & Otsuka, A. (2022). Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergology International, 71(1), 40–46. https://doi.org/10.1016/j.alit.2021.10.004
De Greef, A., Ghislain, P. D., de Montjoye, L., & Baeck, M. (2023). Real-life effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults. Advances in Therapy, 40(5), 2509–2514. https://doi.org/10.1007/s12325-023-02490-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Michalina Grzelka, Jakub Plizga, Agnieszka Głuszczyk, Aleksandra Makłowicz, Ewelina Kopczyńska, Angelika Szpulak, Agata Frańczuk, Julia Głoskowska, Katarzyna Kuleta, Patrycja Karkos
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 102
Number of citations: 0
